BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu XY, Ding HG, Li WG, Xu JH, Han Y, Jia JD, Wei L, Duan ZP, Ling-Hu EQ, Zhuang H. Chinese guidelines on the management of liver cirrhosis (abbreviated version) . World J Gastroenterol 2020; 26(45): 7088-7103 [PMID: 33362370 DOI: 10.3748/wjg.v26.i45.7088] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Hou W, Wu J, Wang K, Wang Z, Wang Z, Chen F, Yu H, Meng Q. Sarcopenia is associated with reduced 5-year survival in cirrhotic patients with age ≥ 65 and Child-Pugh score ≥ 7.. [DOI: 10.21203/rs.3.rs-2251805/v1] [Reference Citation Analysis]
2 Ke Q, Yu X, Wang X, Huang J, Lin B, Wang Z, Huang X, Weng X, Jiao Y, Xie Y, Wu W, Qiu L, Zheng H, Li L, Xu Z, Su Z, Zhuge Y, Liu J, Guo W. Spontaneous portosystemic shunt as a potiential marker for severe liver damage and high risk of complications associated with portal hypertension in patients with hepatitis B-related cirrhosis: a multicenter study from China.. [DOI: 10.21203/rs.3.rs-2179293/v1] [Reference Citation Analysis]
3 Cao YH, Chi P, Zhou C, Lv WF, Quan ZF, Xue FS. The 50% and 95% effective doses of remimazolam tosilate with adjuvant sufentanil for sedation in patients with liver cirrhosis undergoing oesophagogastric varices screening endoscopy. Clinical Pharmacy Therapeu. [DOI: 10.1111/jcpt.13751] [Reference Citation Analysis]
4 Lu D, Jiang Z, Zhai X, Sun Z, Hussein AF. Prognostic Analysis of Liver Cirrhosis Patients with Cerebral Infarction and/or Gastrointestinal Hemorrhage: A Retrospective Cohort Study. Computational and Mathematical Methods in Medicine 2022;2022:1-11. [DOI: 10.1155/2022/2566746] [Reference Citation Analysis]
5 Liao MJ, Li J, Dang W, Chen DB, Qin WY, Chen P, Zhao BG, Ren LY, Xu TF, Chen HS, Liao WJ. Novel index for the prediction of significant liver fibrosis and cirrhosis in chronic hepatitis B patients in China. World J Gastroenterol 2022; 28(27): 3503-3513 [DOI: 10.3748/wjg.v28.i27.3503] [Reference Citation Analysis]
6 Parks LS, Little P. Cirrhosis, Hepatocellular Carcinoma, and Locoregional Therapies. Journal of Radiology Nursing 2022;41:129-135. [DOI: 10.1016/j.jradnu.2022.01.005] [Reference Citation Analysis]
7 Zhang YY, Meng ZJ. Definition and classification of acute-on-chronic liver diseases. World J Clin Cases 2022; 10(15): 4717-4725 [DOI: 10.12998/wjcc.v10.i15.4717] [Reference Citation Analysis]
8 Gillessen A, Angelico F, Chen J, Lu L, Lucena MI, Fu Q, Xie Q, Andrade RJ, Xie W, Xu X, Yu Y, Mao Y, Nan Y. Silymarin for Treating Toxic Liver Disease: International Consensus Recommendations. Gastro Hep Advances 2022;1:882-893. [DOI: 10.1016/j.gastha.2022.05.006] [Reference Citation Analysis]
9 Wu Y, Wu Y, Liu K, Liu H, Wang S, Huang J, Ding H. Identification of Genetic Predisposition in Noncirrhotic Portal Hypertension Patients With Multiple Renal Cysts by Integrated Analysis of Whole-Genome and Single-Cell RNA Sequencing. Front Genet 2021;12:775470. [PMID: 34868264 DOI: 10.3389/fgene.2021.775470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Huang L, Yu Q, Peng H. Hemorheological Alteration in Patients with Cirrhosis Clinically Diagnosed with Portal Vein System Thrombosis After Splenectomy. Med Sci Monit 2021;27:e931157. [PMID: 34120137 DOI: 10.12659/MSM.931157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chen SS, Huang Y, Guo YM, Li SS, Shi Z, Niu M, Zou ZS, Xiao XH, Wang JB. Serum Metabolomic Analysis of Chronic Drug-Induced Liver Injury With or Without Cirrhosis. Front Med (Lausanne) 2021;8:640799. [PMID: 33855035 DOI: 10.3389/fmed.2021.640799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]